Related Experiment Video
Updated: May 11, 2026

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
Challenges and advances in the medical treatment of granulomatous amebic encephalitis
Natasha Spottiswoode1, Julia C Haston2, Natasha W Hanners3
1Division of Infectious Diseases, University of California San Francisco, San Francisco, CA, USA.
Abstract:
Granulomatous amebic encephalitis, caused by the free-living amebae Balamuthia mandrillaris or Acanthamoeba species, is a rare and deadly infectious syndrome with a current mortality rate of >90%. Much work remains to define the optimal treatment for these infections. Here, we provide a comprehensive overview of the supporting evidence behind antimicrobials currently recommended by the Centers for Disease Control and Prevention (CDC) with updated statistics on survival rates and medication usage from the CDC Free-Living Ameba Database. We also discuss promising treatments, especially the emerging therapeutic agent nitroxoline, and provide recommendations for the next steps in this area.
Insights
Granulomatous amebic encephalitis, a deadly infection caused by Balamuthia mandrillaris or Acanthamoeba, has a high mortality rate. This review examines current treatments and explores promising therapies like nitroxoline.
Area of Science:
- Neurology
- Infectious Diseases
- Parasitology
Background:
- Granulomatous amebic encephalitis (GAE) is a rare, severe central nervous system infection.
- Caused by free-living amebae, Balamuthia mandrillaris and Acanthamoeba species.
- GAE has a high mortality rate, exceeding 90%.
Purpose of the Study:
- To provide a comprehensive overview of evidence for current GAE antimicrobial treatments.
- To present updated survival rates and medication usage statistics.
- To discuss emerging treatments, including nitroxoline.
Main Methods:
- Review of supporting evidence for CDC-recommended antimicrobials.
- Analysis of updated statistics from the CDC Free-Living Ameba Database.
- Discussion of promising therapeutic agents.
Main Results:
- Current treatment strategies for GAE are reviewed.
- Updated survival rates and medication usage data are presented.
- Nitroxoline identified as a promising emerging treatment.
Conclusions:
- Optimal treatment for GAE requires further definition.
- Evidence supports current CDC-recommended antimicrobials.
- Nitroxoline shows potential for future GAE therapy.
More Related Videos
06:57Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
Published on: May 12, 2023
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Related Concept Videos
Acute Pyelonephritis II: Diagnostic Studies and Management
Bacterial Meningitis I: Introduction
Bacterial Meningitis II: Pathophysiology
Encephalitis l: Introduction
Encephalitis ll: Pathophysiology
Brain Abscess l: Introduction